Corcept Therapeutics (CORT) Gross Profit (2012 - 2026)

Corcept Therapeutics has disclosed Gross Profit across 15 years of filings, most recently posting $162.0 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $162.0 million, up 4.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $755.6 million (up 12.0% YoY), and the FY2025 annual result was $748.4 million, up 12.69% from the prior year.
• Gross Profit came in at $162.0 million for Q1 2026 at Corcept Therapeutics, down from $199.6 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $203.0 million in Q3 2025 to a low of $92.4 million in Q1 2022.
• The 5-year median for Gross Profit is $144.3 million (2024), against an average of $143.9 million.
• Across the five-year window, Gross Profit gained 4.21% in 2022 and surged 47.33% in 2024, its largest moves.
• Corcept Therapeutics' Gross Profit stood at $101.6 million in 2022, then surged by 31.46% to $133.5 million in 2023, then soared by 34.0% to $178.9 million in 2024, then climbed by 11.54% to $199.6 million in 2025, then retreated by 18.82% to $162.0 million in 2026.
• The last three Gross Profit figures came in at $162.0 million (Q1 2026), $199.6 million (Q4 2025), and $203.0 million (Q3 2025), per Business Quant data.